Ionis Pharmaceuticals reported positive Phase 3 results for Tryngolza in severe hypertriglyceridemia (sHTG), demonstrating significant reductions in triglyceride levels and pancreatitis prevention in two large trials, Core and Core2. The company plans to file for FDA label expansion by year-end to cover severely elevated triglycerides, beyond its existing indication for familial chylomicronemia syndrome. Tryngolza, Ionis’ first fully owned drug, showed up to 73% triglyceride reduction and addresses a growing obesity and diabetes-associated patient population. Shares surged over 30% on the news, reflecting strong market potential for this multi-billion dollar opportunity.